Clinical Trials Logo

Non-Small Cell Lung Cancer clinical trials

View clinical trials related to Non-Small Cell Lung Cancer.

Filter by:

NCT ID: NCT04335292 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge

OCELOT
Start date: January 6, 2021
Phase: Phase 2
Study type: Interventional

This phase II single-armed study will examine the clinical utility of retreating patients with osimertinib, in the third-line, following first-line treatment with osimertinib and second-line treatment with platinum and pemetrexed chemotherapy. The current standard of care for first-line Epidermal Growth Factor Receptor (EGFR) mutated Advanced Non-Small Cell Lung Cancer (aNSCLC) is osimertinib, followed by cytotoxic chemotherapy. The repeat of osimertinib following previous treatment failure is investigational, although supported by scientific rationale. The dosing and scheduling of osimertinib follows its use in approved settings. The investigators examine its tolerability and efficacy in this setting to ensure osimertinib is a safe third-line option for patients with Epidermal Growth Factor Receptor mutated (EGFR+) Advanced Non-Small Cell Lung Cancer(aNSCLC).

NCT ID: NCT04332367 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.

NCT ID: NCT04324164 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Start date: March 24, 2020
Phase:
Study type: Observational

This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

NCT ID: NCT04324151 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

Start date: March 24, 2020
Phase:
Study type: Observational

This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

NCT ID: NCT04324125 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

Start date: March 24, 2020
Phase:
Study type: Observational

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.

NCT ID: NCT04322890 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

PIKACHU
Start date: April 16, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

NCT ID: NCT04322617 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

ATHENA
Start date: March 24, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.

NCT ID: NCT04322591 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial

POSEIDON
Start date: March 24, 2020
Phase:
Study type: Observational

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.

NCT ID: NCT04322578 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

CONFIRM
Start date: March 24, 2020
Phase: Phase 2
Study type: Interventional

This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer

NCT ID: NCT04317651 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

SPECIALK
Start date: May 16, 2019
Phase:
Study type: Observational

This is a multicenter, observational, retrospective cohort study aimed at assessing the efficacy and safety of crizotinib in ALK positive NSCLC treated in real life setting.